Polymeric treatment compositions

Patent metadata

Field	Value
Publication number	US-9351993-B2
Application number	US-201313917323-A
Country	US
Kind code	B2
Filing date	Jun 13, 2013
Priority date	Jun 14, 2012
Publication date	May 31, 2016
Grant date	May 31, 2016

Abstract

Compositions are described comprising a polymer; a non-physiological pH solution; and a visualization agent; wherein the polymer is soluble in the non-physiological pH solution and insoluble at a physiological pH. Methods of forming the solutions and polymers are disclosed as well as methods of therapeutic use.

First claim

We claim:

1. A composition comprising:
a biocompatible polymer comprising:
a first monomer selected from a group consisting of aminopropyl methacrylamide, aminoethyl methacrylamide, N-(3-methylphridine)acrylamide, N-(2-(4-aminophenyl)ethylacrylamide, N-(4-aminobenzyl)acrylamide, N-(2-4-imidazolyl)ethyl)acrylamide and combinations thereof;
a second monomer selected from a group consisting of t-butyl acrylate, t-butyl acrylamide, n-octyl methacrylate, methyl methacrylate, hydroxyethyl methacrylate, hydroxyethyl acrylate, hydroxypropyl methacrylate, hydroxybutyl methacrylate, derivatives thereof or combinations thereof;
an aqueous solution with a non-physiological pH; and
a visualization agent; wherein the visualization agent is an iodinated compound, barium sulfate tantalum, superparamagnetic iron oxide, gadolinium molecules or a combination thereof;
wherein the biocompatible polymer is soluble in the aqueous solution and insoluble at a physiological pH at a treatment site.

2. The composition of claim 1 , wherein the visualization agent is a particulate.

3. The composition of claim 1 , wherein the visualization agent has a concentration of about 5% to about 65%.

4. The composition of claim 1 , wherein the polymer is a reaction product of three different monomers.

5. The composition of claim 1 , wherein the non-physiological pH solution is water.

6. The composition of claim 1 , wherein the non-physiological pH solution has a pH of less than about 6.

7. The composition of claim 1 , wherein the non-physiological pH solution has a pH of greater than about 8.

8. The composition of claim 1 , wherein the polymer has a concentration of about 1% w/w to about 35% w/w.

9. A composition comprising:
a first aqueous solution at non-physiological pH;
a polymer comprising:
a first monomer selected from a group consisting of aminopropyl methacrylamide, aminoethyl methacrylamide, N-(3-methylpyridine)acrylamide, N-(2-(4-aminophenyl)ethylacrylamide, N-(4-aminobenzyl)acrylamide, N-(2-4-imidazolyl)ethyl)acrylamide and combinations thereof;
a second monomer selected from a group consisting of t-butyl acrylate, t-butyl acrylamide, n-octyl methacrylate, methyl methacrylate, hydroxyethyl methacrylate, hydroxyethyl acrylate, hydroxypropyl methacrylate, hydroxybutyl methacrylate, derivatives thereof or combinations thereof;
wherein the polymer has a concentration of from about 1% to 35% w/w, that is soluble in the first aqueous solution at non-physiological pH and insoluble in a second aqueous solution at physiological pH; and
a particulate visualization agent at a concentration of from about 20% w/w to about 60% w/w, wherein the visualization agent is an iodinated compound, barium sulfate, tantalum, superparamagnetic iron oxide, gadolinium molecules or a combination thereof.

Assignees

• Microvention Inc

Inventors

• Cruise Gregory M
• Constant Michael J
• Garretson Joshua

Classifications

• A61P9/00

  Drugs for disorders of the cardiovascular system · CPC title

• A61K31/78

  of acrylic acid or derivatives thereof · CPC title

• A61K9/0024

  Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue (compositions for intravenous administration, normal injectable solutions or dispersions for, e.g. subcutaneous administration A61K9/0019; brain implants A61K9/0085; (coated) prostheses, catheters or stents A61L) · CPC title

• A61L24/0089

  containing inorganic fillers not covered by groups A61L24/0078 or A61L24/0084 · CPC title

• A61L24/046

  obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds (A61L24/043 takes precedence) · CPC title